Structure-activity relationship between PKC412 analogs and SYK... | Download Scientific Diagram
Evolving Therapeutic Options for Acute Myeloid Leukemia
PKC412 - LKT Labs
Isobolograms of simultaneous exposure to PKC412 and conventional... | Download Scientific Diagram
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia | Leukemia
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations | Oncogene
Primary clinical resistance to PKC412 therapy in an AML patient with... | Download Scientific Diagram
Alliance -
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function | Haematologica
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect
Dose–response curves of PKC412 for MOLM13, MOLM14, MV4-11, KOPB-26,... | Download Scientific Diagram
Midostaurin (PKC412) | CAS:120685-11-2 | PKC inhibitor | High Purity | Manufacturer BioCrick
Midostaurin: an emerging treatment for acute myeloid leukemia patients | JBM
CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML - Waldeck - 2020 - Molecular Oncology - Wiley Online Library
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia | Bone Marrow Transplantation
![PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b825a5d927ce38433166e20b17c67b5fa1f2f0b6/6-Table6-1.png "PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar")
PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development - Kiyoi - 2020 - Cancer Science - Wiley Online Library
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology
Jan 04 nwsltr working - The Life Raft Group
A) Comparison of rate of proliferation of MOLM13-S, MOLM13-R-PKC412... | Download Scientific Diagram
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or
Frontiers | Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
Inhibition of FLT3-ITD signaling by AG1295 or PKC412 leads to induction... | Download Scientific Diagram
